| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Brexanolone (USAN/INN); Zulresso (TN) | ||||||
| Product | ZULRESSO (Sage Therapeutics) | ||||||
| Formula | C21H34O2 | ||||||
| Exact mass | 318.2559 | ||||||
| Mol weight | 318.4935 | ||||||
| Structure |  | ||||||
| Simcomp | |||||||
| Remark |
| ||||||
| Efficacy | Antidepressant, Antiepileptic, GABA-A receptor modulator | ||||||
| Comment | Treatment of refractory status epilepticus, postpartum depression (PPD) | ||||||
| Target | GABR [HSA:2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 55879] [KO:K05175 K05181 K05184 K05185 K05186 K05189 K05192] | ||||||
| Pathway |
| ||||||
| Brite | Target-based classification of drugs [BR:br08310] Ion channels Ligand-gated ion channels GABA (ionotropic) GABR D11149 Brexanolone (USAN/INN) <US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D11149 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11149 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 23 1 C1y C 19.7966 -17.1290 2 C1y C 18.5330 -16.4972 3 C1y C 20.9198 -16.4972 4 C1x C 19.7966 -18.5330 5 C1z C 17.4098 -17.1290 6 C1x C 18.5330 -15.0932 7 C1z C 20.9198 -15.0932 8 C1x C 23.3066 -16.4972 9 C1x C 18.6032 -19.1648 10 C1y C 17.4098 -18.5330 11 C1x C 16.2164 -16.4972 12 C1a C 17.4096 -15.5846 13 C1x C 19.7264 -14.4614 14 C1y C 22.1132 -14.3912 15 C1x C 23.3066 -15.0932 16 C1x C 16.2164 -19.1648 17 C1x C 15.0932 -17.1290 18 C5a C 22.1132 -13.0574 19 C1y C 15.0932 -18.5330 20 C1a C 23.3066 -12.4256 21 C1a C 20.9198 -13.7594 22 O1a O 13.8998 -19.1648 23 O5a O 20.9900 -12.4256 BOND 26 1 3 8 1 2 4 9 1 3 5 10 1 4 5 11 1 5 5 12 1 #Up 6 6 13 1 7 7 14 1 8 8 15 1 9 10 16 1 10 11 17 1 11 14 18 1 #Up 12 16 19 1 13 18 20 1 14 7 13 1 15 9 10 1 16 14 15 1 17 17 19 1 18 7 21 1 #Up 19 1 2 1 20 1 3 1 21 1 4 1 22 2 5 1 23 2 6 1 24 19 22 1 #Down 25 3 7 1 26 18 23 2 |